tbuckley/cabot-search huggingface dataset:
Opioid Epidemic in Appalachia Receives USDA Telemedicine Funding
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Telemedicine is becoming increasingly popular: visits by rural Medicare beneficiaries increased 28% per year between 2004 and 2013, with 107 955 telemedicine visits in 2013 (Mehrotra A et al. JAMA. 2016;315[18]:2015-2016).
A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial
Authors: D. Malka, T. Trarbach, L. Fartoux, J. Mendiboure, C. de la Fouchardière, F. Viret, E. Assenat, E. Boucher, O. Rosmorduc, T. Greten
Journal: Journal of Clinical Oncology (2009)

4520 Background: There is no standard regimen for palliative chemotherapy of advanced biliary cancers. The GEMOX regimen is an option (BJC 2008). EGFR over-expression has been observed in advanced biliary cancers suggesting that the combination with anti-EGFR monoclonal antibodies may be appropriate. Methods: Patients with advanced biliary cancer, WHO performance status 0–1, and without prior palliative chemotherapy were eligible for this international, open-label, two-stage, randomized phase II trial. Patients received GEMOX (gemcitabine, 1000 mg/m 2 [10 mg/m 2 /min] at day [D]1; oxaliplatin, 100 mg/m 2 at D2) alone (arm A) or with cetuximab (500 mg/m 2 at D1 or 2, arm B), every 2 weeks. Randomization was stratified according to tumor stage and location, center, and prior treatments. The primary endpoint was 4-month crude progression-free survival (PFS) rate (H0 hypothesis, &lt; 40%; H1, ≥ 60%; planned sample size, 50 patients per arm). Secondary endpoints were response rate, PFS, overall survival, toxicity, early response assessment by PET, and blood/tumor EGFR signalling pathway member analyses. A data safety monitoring board-approved interim analysis was performed at the end of the first stage (18 patients per arm, minimal follow- up 4 months). Results: From October 2007 to October 2008, we enrolled 101 patients (median age, 62 yrs; male, 60%; metastatic, 86%; non-gallbladder, 76%). Among the 36 patients at the time of the interim analysis, the median number of treatment cycles was 6 and 8 in arms A and B, respectively. 76% (arm A) and 67% (arm B) had NCI-CTC grade 3–4 toxicity, mainly cytopenia (41%/39%), peripheral neuropathy (modified Levi's scale grade 2–3: 29%/33%), fatigue (6%/22%), gastrointestinal toxicity (12%/17%), and rash/hypersensitivity (0%/17%). The 4-month PFS rate was 44% (95% CI, 20–70) and 61% (95% CI, 36–83) in arms A and B, respectively. Conclusions: The GEMOX-cetuximab regimen seems well tolerated in patients with advanced biliary cancer. Adding cetuximab to GEMOX showed promising activity and therefore the trial was continued. Updated results on the whole population for primary and secondary endpoints will be available at the meeting. [Table: see text]
The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM)
Authors: Guang Yang, Christina Hanzis, Sigitas Verselis, Lian Xu, Zachary Hunter, Leukothea Ioakimidis, Patricia Sheehy, Christopher Patterson, Edward Fox, Steven P. Treon
Journal: Blood (2010)
Protective Ventilation for Patients Without Acute Respiratory Distress Syndrome
Authors: Zhongheng Zhang
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A coding variant in<i>FTO</i>confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD
Authors: Han Sang Kim, Jae Hee Cheon, Eun Suk Jung, Joonhee Park, Sowon Aum, Soo Jung Park, Sungho Eun, Jinu Lee, Ulrich Rüther, Giles S H Yeo, Marcella Ma, Kyong Soo Park, Takeo Naito, Yoichi Kakuta, Ji Hyun Lee, Won Ho Kim, Min Goo Lee
Journal: Gut (2016)

Myelosuppression is a life-threatening complication of thiopurine therapy, and the incidence of thiopurine-induced myelosuppression is higher in East Asians than in Europeans. We investigated genetic factors associated with thiopurine-induced leukopenia in patients with IBD.A genome-wide association study (GWAS) was conducted in thiopurine-treated patients with IBD, followed by high-throughput sequencing of genes identified as significant in the GWAS or those involved in thiopurine metabolism (n=331). Significant loci associated with thiopurine-induced leukopenia were validated in two additional replication cohorts (n=437 and n=330). Functional consequences of FTO (fat mass and obesity-associated) variant were examined both in vitro and in vivo.The GWAS identified two loci associated with thiopurine-induced leukopenia (rs16957920, FTO intron; rs2834826, RUNX1 intergenic). High-throughput targeted sequencing indicated that an FTO coding variant (rs79206939, p.A134T) linked to rs16957920 is associated with thiopurine-induced leukopenia. This result was further validated in two replication cohorts (combined p=1.3×10-8, OR=4.3). The frequency of FTO p.A134T is 5.1% in Koreans but less than 0.1% in Western populations. The p.A134T variation reduced FTO activity by 65% in the nucleotide demethylase assay. In vivo experiments revealed that Fto-/- and Fto+/- mice were more susceptible to thiopurine-induced myelosuppression than wild-type mice.The results suggest that the hypomorphic FTO p.A134T variant is associated with thiopurine-induced leukopenia. These results shed light on the novel physiological role of FTO and provide a potential pharmacogenetic biomarker for thiopurine therapy.
Ramifications of New Terminology for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma—Reply
Authors: Yuri E. Nikiforov
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)
Authors: J. L. Raoul, R. S. Finn, Y. K. Kang, J. W. Park, R. Harris, V. Coric, M. Donica, I. Walters
Journal: Journal of Clinical Oncology (2009)

4577 Background: Brivanib is an orally available dual inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signaling. FGF pathway activation is of increasing importance in the setting of liver fibrosis and HCC. This phase II study aimed to assess the efficacy and safety of brivanib in patients (pts) with unresectable, locally advanced or metastatic HCC who had received either no prior systemic therapy (Cohort A) or one prior regimen of angiogenesis inhibitor (Cohort B). Methods: Eligible pts had biopsy-proven HCC or had radiological evidence of HCC and were serology positive for Hep B or C with alpha fetoprotein levels ≥ 400 μg/L. Pts received brivanib 800 mg qd. Efficacy endpoints included OS, PFS, TTP, ORR, and DCR. Safety was assessed throughout the study. Serum levels of a biomarker, Collagen IV (a component of the basement membrane of blood vessels), were measured on day 1, weeks 3 and 6, and at end of treatment. Results: Interim results are reported. From December 2006 to October 2008, 96 patients were enrolled (Cohort A: 55 pts; Cohort B: 41 pts). In Cohort B, 38 pts had failed sorafenib and 3 had failed thalidomide. In Cohort A, median OS (95% CI) was 10 (6.8,-) months. Most frequently reported grade 3/4 AEs were fatigue (16%), AST elevation (19%), and hyponatremia (41%) in Cohort A and hypertension (7.3%), diarrhea (4.9%), and headache (4.9%) in Cohort B. 24 pts died in Cohort A and 5 pts in Cohort B, none were considered treatment-related. Treatment-induced reductions in serum Collagen IV appear to correlate with long term outcome (PFS and OS). Conclusions: Brivanib has activity as both first-line and second-line post-sorafenib systemic treatment in HCC. Collagen IV, a novel serum angiogenic biomarker, appears to be associated with outcome. [Table: see text] [Table: see text]
Maintenance immunotherapy for primary central nervous system lymphoma following complete response after first-line chemotherapy.
Authors: Nancy Diane Doolittle, Rochelle Fu, Prakash Ambady, Jenny Firkins, Edward A. Neuwelt
Journal: Journal of Clinical Oncology (2016)

e13531 Background: High response rates have been reported following high-dose methotrexate (MTX)-based regimens for newly diagnosed primary central nervous system lymphoma (PCNSL). However maintaining durable response is difficult; in the OHSU series (n = 128), 47 of the 75 patients (pts) who achieved complete response (CR) recurred. Little is known about the etiology and mechanism of PCNSL recurrence. Jahnke et al (JCO, 2006) suggested recurrence may be due to seeding from subclinical sites outside the CNS. If correct, systemic exposure to immunotherapy may provide adequate protection. A second mechanism may be due to dormant PCNSL cells behind the blood-brain barrier, often distant from original site of brain disease, but not merely regrowth of residual tumor. Based on pre-clinical and clinical studies by Muldoon (2011) and Ney & Abrey (2009), maintenance immunotherapy after CR to first-line treatment may extend response duration. Methods: We obtained IRB approval to review CD20+ PCNSL pts treated with maintenance rituximab following radiographic CR after first-line MTX-based chemotherapy. Rituximab (750 mg/m2) was infused every 2 or 3 mo. Pts were treated between 2008 and 2015. Results: Nine pts received maintenance. The median interval from CR date to initiation of maintenance was 7.4 mo (range: 1.3 to 37.7), median duration of maintenance was 31.3 mo (range: 9.4 to 72.1), and median CR duration was 38.7 mo (range: 10.6 to 85.6). Two pts recurred; one recurred in brain 4.6 yrs after CR and 3.7 yrs after starting maintenance; and one in eyes 5.9 yrs after CR and 4.5 yrs after starting maintenance. Eight pts are alive; one had 4.1 yrs of maintenance and died of coronary disease 7.1 yrs after CR. Conclusions: These results suggest maintenance immunotherapy warrants further investigation in CD20+ PCNSL. In view of efficacy of obinutuzumab for CD20+ indolent non-Hodgkin lymphoma (Sehn, ASCO 2015), we hypothesize that maintenance obinutuzumab will prolong CR duration and provide insight into the mechanism of PCNSL recurrence. We are starting an investigator initiated randomized trial of maintenance obinutuzumab vs. observation for pts who achieve CR after first-line MTX-based therapy.
Metastatic well or moderately differentiated Neuroendocrine tumors (WDNET) treated with sequences of different Somatostatin Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): a single center experience
Authors: R. Marconcini, S. Ricci, L. Galli, A. Antonuzzo, A. Farnesi, L. Derosa, E. Biasco, A. Falcone
Journal: Annals of Oncology (2015)
Greyscale—A Mystery Dermatologic Disease on HBO’s<i>Game of Thrones</i>
Authors: Jules B. Lipoff
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Remission in systemic lupus erythematosus: durable remission is rare
Authors: Theresa R Wilhelm, Laurence S Magder, Michelle Petri
Journal: Annals of the Rheumatic Diseases (2016)

Introduction Remission is the ultimate goal in systemic lupus erythematosus (SLE). In this study, we applied four definitions of remission agreed on by an international collaboration (Definitions of Remission in SLE, DORIS) to a large clinical cohort to estimate rates and predictors of remission. Methods We applied the DORIS definitions of Clinical Remission, Complete Remission (requiring negative serologies), Clinical Remission on treatment (ROT) and Complete ROT. 2307 patients entered the cohort from 1987 to 2014 and were seen at least quarterly. Patients not in remission at cohort entry were followed prospectively. We used the Kaplan-Meier approach to estimate the time to remission and the time from remission to relapse. Cox regression was used to identify baseline factors associated with time to remission, adjusting for baseline disease activity and baseline treatment. Results The median time to remission was 8.7, 11.0, 1.8 and 3.1 years for Clinical Remission, Complete Remission, Clinical ROT and Complete ROT, respectively. High baseline treatment was the major predictor of a longer time to remission, followed by high baseline activity. The median duration of remission for all definitions was 3 months. African-American ethnicity, baseline low C3 and baseline haematological activity were associated with longer time to remission for all definitions. Baseline anti-dsDNA and baseline low C4 were associated with longer time to Complete Remission and Complete ROT. Baseline low C4 was also negatively associated with Clinical Remission. Conclusions Our results provide further insights into the frequency and duration of remission in SLE and call attention to the major role of baseline activity and baseline treatment in predicting remission.
Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research
Authors: Sally Arai, Mukta Arora, Tao Wang, Wensheng He, Daniel R. Couriel, Alvaro Urbano-Ispizua, Corey S. Cutler, Stephen Spellman, Steven Z. Pavletic
Journal: Blood (2013)
Treating Chronic Knee Pain With Acupuncture
Authors: Johannes Fleckenstein, Winfried Banzer
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interventions for Treatment of Depression in Primary Care—Reply
Authors: Martha L. Bruce, George S. Alexopoulos, Herbert C. Schulberg, Thomas Ten Have, Ira R. Katz, Charles F. Reynolds III
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Taxane-based adjuvant therapy for early breast cancer (EBC): A meta-analysis of the predictive effect of ER and HER2 status.
Authors: M. De Laurentiis, C. Criscitiello, M. Giuliano, A. Giordano, D. Cianniello, A. Montanino, C. Falato, R. Caputo, B. Stanzione, S. De Placido
Journal: Journal of Clinical Oncology (2010)

e11025 Background: Taxane-based adjuvant chemotherapy regimens for EBC yield on average an improvement of disease-free-survival (DFS) and overall survival (OS) as compared to anthracycline-based regimens (De Laurentiis et al., JCO 2008). It has been questioned, however, that this average benefit may results from a markedly improved outcome for some subsets of patients, with others not receiving any advantage. To check this hypothesis, we performed a meta-analysis of the predictive effects both of HER2 and of ER status by pooling subsets data of the available randomized trials (RTs). The efficacy of taxane-based regimens in the subgroup of triple-negative (TN) pts was also evaluated. Methods: We searched the Pubmed database to identify randomized trials that compared taxane-based with non-taxane-based adjuvant chemotherapy regimens for EBC and reported efficacy data according to: HER2 or ER or the combination HER2/ER or the TN status. We also searched the proceedings of major international conferences to identify relevant trials with subset analyses. Hazard ratios (HRs) for DFS were pooled across the studies by inverse variance weighting and are reported with their 95% confidence intervals (95% CIs). HRs <1 indicate an advantage for taxane-based regimens. Results: See Table. Conclusions: This meta-analysis suggests that HER2 status is a statistically significant predicitive factor for taxane-based adjuvant regimens. When HER2 is not overexpressed, taxanes seem to yield no significant advantage irrespective of ER status or TN status. Confirmatory studies are warranted. Subgroup No. studies No. patients HR 95% CIs Test for interaction ER+ 19 23,307 0.89 0.85-0.94 p=0.29 ER- 9,208 0.86 0.81-0.91 HER2+ 9 3,749 0.79 0.72-0.87 p=0.001 HER2- 11,074 0.94 0.89-1.00 HER2+/ER+ 5 - 0.80 0.70-0.92 p=0.03 HER2+/ER- - 0.81 0.70-0.94 HER2-/ER+ - 0.98 0.91-1.05 HER2-/ER- - 0.92 0.84-1.01 Triple-negative 7 - 0.95 0.87-1.04 N/A Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis sanofi-aventis
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis
Authors: Raoel Maan, Marjolein van Tilborg, Katja Deterding, Alnoor Ramji, Adriaan J. van der Meer, Florence Wong, Scott Fung, Morris Sherman, Michael P. Manns, Markus Cornberg, Bettina E. Hansen, Heiner Wedemeyer, Harry L.A. Janssen, Robert J. de Knegt, Jordan J. Feld
Journal: Clinical Gastroenterology and Hepatology (2016)
Whole-Body Diffusion-Weighted Magnetic Resonance Imaging Is a New Sensitive Non-Invasive Method for Staging and Monitoring Chemotherapy Response of Malignant Lymphoma Including Indolent Lymphoma Compared with FDG-PET/CT
Authors: Shinji Kishi, Tatsuro Tsuchida, Takahiro Yamauchi, Naoko Hosono, Satoshi Ikegaya, Yoshimasa Urasaki, Hidehiko Okazawa, Hirohiko Kimura, Takanori Ueda
Journal: Blood (2010)
Health Professionals With Physical Disabilities
Authors: Michelle Nashleanas
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal